Robert Wesolowski is an Oncology physician affiliated with The Ohio State University Comprehensive Cancer Center. OpenAlex indexes 399 publications with 4,988 citations (h-index 36); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
460 W 10th Ave
Columbus, OH 432101240
Telephone
614-293-6529Provider last certified this registry record 10 Apr 2024.
Clinical trials
- Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors
Sponsor: Ohio State University Comprehensive Cancer Center
- Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer
Sponsor: National Cancer Institute (NCI)
- Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
Sponsor: Robert Wesolowski
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20251 payment
- PFIZER INC.Program year20241 payment
- Eisai Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
85.5%Aromatase Inhibitor38.9%Anastrozole63%Letrozole20%Exemestane18%Part D<11 patientsKinase inhibitor38.9%Ibrance79%Kisqali21%Part D<11 patients+ 1 more class in this area
Nervous system
14.5%Phenothiazine8.1%Prochlorperazine Maleate100%Part D≥16 patientsGabapentinoids6.4%Gabapentin100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2022–2024 per NIH RePORTER. The latest:
- Training Hematology and Oncology Fellows in Clinical Research
Ohio State University
FY2024$179,597T32CA247815 - Training Hematology and Oncology Fellows in Clinical Research
Ohio State University
FY2023$174,042T32CA247815 - Training Hematology and Oncology Fellows in Clinical Research
Ohio State University
FY2022$164,454T32CA247815
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Otterson, MD
The Ohio State University Comprehensive Cancer Center
Raphael Pollock, MD, PhD
The Ohio State University Comprehensive Cancer Center
Steven Clinton, MD
The Ohio State University Comprehensive Cancer Center
Claire Verschraegen, MD
The Ohio State University Comprehensive Cancer Center
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”